ea0035p597 | Endocrine tumours and neoplasia | ECE2014
Cuadro Alberto Torres
, Rodriguez Jose Perez
, Tamarit Ana Albero
, Hernandez Tomas Martin
, Rivera Natividad Gonzalez
, Zoilo Juan Jose Reina
, Carrasco Fernando Henao
, Merino Luis De La Cruz
Introduction: Everolimus is a drug selective inhibitor of mTOR. In 2012 a Phase 2 study* of everolimus monotherapy demonstrated modest efficacy in patients with pheochromocytomas/paragangliomas. Our objective was to evaluate the efficacy and safety of everolimus in a patient with paraganglioma. (*Phase 2 study of everolimus monotherapy in patient with nonfunctioning neuroendocrine tumor or pheochromocytomas/paraglangliomas. Do-Young Oh et al. Cancer 2012 <str...